The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases - PubMed (original) (raw)
. 1996 Apr 26;271(17):10079-86.
doi: 10.1074/jbc.271.17.10079.
Affiliations
- PMID: 8626565
- DOI: 10.1074/jbc.271.17.10079
Free article
The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases
J M Whitelock et al. J Biol Chem. 1996.
Free article
Abstract
Perlecan is a modular heparan sulfate proteoglycan that is localized to cell surfaces and within basement membranes. Its ability to interact with basic fibroblast growth factor (bFGF) suggests a central role in angiogenesis during development, wound healing, and tumor invasion. In the present study we investigated, using domain specific anti-perlecan monoclonal antibodies, the binding site of bFGF on human endothelial perlecan and its cleavage by proteolytic and glycolytic enzymes. The heparan sulfate was removed from perlecan by heparitinase treatment, and the approximately 450-kDa protein core was digested with various proteases. Plasmin digestion resulted in a large fragment of approximately 300 kDa, whereas stromelysin and rat collagenase cleaved the protein core into smaller fragments. All three proteases removed immunoreactivity toward the anti-domain I antibody. We showed also that perlecan bound bFGF specifically by the heparan sulfate chains located on the amino-terminal domain I. Once bound, the growth factor was released very efficiently by stromelysin, rat collagenase, plasmin, heparitinase I, platelet extract, and heparin. Interestingly, heparinase I, an enzyme with a substrate specificity for regions of heparan sulfate similar to those that bind bFGF, released only small amounts of bFGF. Our findings provide direct evidence that bFGF binds to heparan sulfate sequences attached to domain I and support the hypothesis that perlecan represents a major storage site for this growth factor in the blood vessel wall. Moreover, the concerted action of proteases that degrade the protein core and heparanases that remove the heparan sulfate may modulate the bioavailability of the growth factor.
Similar articles
- Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation.
Saksela O, Moscatelli D, Sommer A, Rifkin DB. Saksela O, et al. J Cell Biol. 1988 Aug;107(2):743-51. doi: 10.1083/jcb.107.2.743. J Cell Biol. 1988. PMID: 2971068 Free PMC article.
Cited by
- Proteoglycan form and function: A comprehensive nomenclature of proteoglycans.
Iozzo RV, Schaefer L. Iozzo RV, et al. Matrix Biol. 2015 Mar;42:11-55. doi: 10.1016/j.matbio.2015.02.003. Epub 2015 Feb 18. Matrix Biol. 2015. PMID: 25701227 Free PMC article. Review. - Human pancreatic precursor cells secrete FGF2 to stimulate clustering into hormone-expressing islet-like cell aggregates.
Hardikar AA, Marcus-Samuels B, Geras-Raaka E, Raaka BM, Gershengorn MC. Hardikar AA, et al. Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7117-22. doi: 10.1073/pnas.1232230100. Epub 2003 May 30. Proc Natl Acad Sci U S A. 2003. PMID: 12799459 Free PMC article. - Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning.
Vempati P, Popel AS, Mac Gabhann F. Vempati P, et al. Cytokine Growth Factor Rev. 2014 Feb;25(1):1-19. doi: 10.1016/j.cytogfr.2013.11.002. Epub 2013 Nov 27. Cytokine Growth Factor Rev. 2014. PMID: 24332926 Free PMC article. Review. - Serglycin is a major proteoglycan in polarized human endothelial cells and is implicated in the secretion of the chemokine GROalpha/CXCL1.
Meen AJ, Øynebråten I, Reine TM, Duelli A, Svennevig K, Pejler G, Jenssen T, Kolset SO. Meen AJ, et al. J Biol Chem. 2011 Jan 28;286(4):2636-47. doi: 10.1074/jbc.M110.151944. Epub 2010 Nov 12. J Biol Chem. 2011. PMID: 21075844 Free PMC article. - Cancer Metastasis: The Role of the Extracellular Matrix and the Heparan Sulfate Proteoglycan Perlecan.
Elgundi Z, Papanicolaou M, Major G, Cox TR, Melrose J, Whitelock JM, Farrugia BL. Elgundi Z, et al. Front Oncol. 2020 Jan 17;9:1482. doi: 10.3389/fonc.2019.01482. eCollection 2019. Front Oncol. 2020. PMID: 32010611 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources